DE60115667D1 - Säureempfindliche verbindungen, deren herstellung und verwendungen - Google Patents
Säureempfindliche verbindungen, deren herstellung und verwendungenInfo
- Publication number
- DE60115667D1 DE60115667D1 DE60115667T DE60115667T DE60115667D1 DE 60115667 D1 DE60115667 D1 DE 60115667D1 DE 60115667 T DE60115667 T DE 60115667T DE 60115667 T DE60115667 T DE 60115667T DE 60115667 D1 DE60115667 D1 DE 60115667D1
- Authority
- DE
- Germany
- Prior art keywords
- acid
- acidic
- compounds
- biologically active
- sensitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Polyethers (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0011278 | 2000-09-05 | ||
FR0011278A FR2813605B1 (fr) | 2000-09-05 | 2000-09-05 | Composes acidosensibles, leur preparation et utilisations |
US23911600P | 2000-10-11 | 2000-10-11 | |
US239116P | 2000-10-11 | ||
PCT/FR2001/002725 WO2002020510A1 (fr) | 2000-09-05 | 2001-09-03 | Composes acidosensibles, leur preparation et utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60115667D1 true DE60115667D1 (de) | 2006-01-12 |
DE60115667T2 DE60115667T2 (de) | 2006-08-24 |
Family
ID=26212598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60115667T Expired - Lifetime DE60115667T2 (de) | 2000-09-05 | 2001-09-03 | Säureempfindliche verbindungen, deren herstellung und verwendungen |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050085426A1 (de) |
EP (1) | EP1317439B1 (de) |
JP (1) | JP2004508364A (de) |
KR (1) | KR20030040441A (de) |
CN (1) | CN1452617A (de) |
AT (1) | ATE312088T1 (de) |
AU (1) | AU2001287801A1 (de) |
CA (1) | CA2421179A1 (de) |
DE (1) | DE60115667T2 (de) |
HU (1) | HUP0303379A3 (de) |
IL (1) | IL154736A0 (de) |
MX (1) | MXPA03001876A (de) |
WO (1) | WO2002020510A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2338789T3 (es) | 2003-06-18 | 2010-05-12 | Tranzyme Pharma Inc. | Antagonistas macrociclicos del receptor de motilina. |
FR2925491B1 (fr) * | 2007-12-19 | 2010-09-03 | Oz Biosciences Sas | Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules |
KR101014246B1 (ko) | 2008-07-03 | 2011-02-16 | 포항공과대학교 산학협력단 | 페하 민감성 금속 나노 입자 및 이의 제조 방법. |
GB201307438D0 (en) * | 2013-04-25 | 2013-06-05 | Airbus Uk Ltd | Fuel Additive |
KR101725240B1 (ko) | 2015-03-24 | 2017-04-11 | 부산대학교 산학협력단 | UV-광 반응성 및 pH 반응성을 갖는 이중 자극 반응성 코어-쉘 자성나노입자 및 이를 포함하는 약물 전달체 |
EP3095790A1 (de) | 2015-05-22 | 2016-11-23 | Universite De Bordeaux | Nukleosidlipidverbindungen mit ph-empfindlichen dialkylorthoesterketten und deren verwendung zum transport oder zur vektorisierung von mindestens einem therapeutischen wirkstoff |
CN111771114A (zh) * | 2018-02-26 | 2020-10-13 | 沃特世科技公司 | 对酸不稳定的表面活性剂及用于执行蛋白质溶解或酶消化的方法 |
CN116656706A (zh) * | 2023-04-18 | 2023-08-29 | 河南中医药大学第一附属医院 | 一种酸敏融合蛋白重组质粒及其构建、应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4406686A (en) * | 1981-07-24 | 1983-09-27 | Stauffer Chemical Company | Haloalkylaminomethyldioxolane herbicide antidotes |
FR2722506B1 (fr) * | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
-
2001
- 2001-09-03 WO PCT/FR2001/002725 patent/WO2002020510A1/fr active IP Right Grant
- 2001-09-03 MX MXPA03001876A patent/MXPA03001876A/es unknown
- 2001-09-03 EP EP01967418A patent/EP1317439B1/de not_active Expired - Lifetime
- 2001-09-03 IL IL15473601A patent/IL154736A0/xx unknown
- 2001-09-03 DE DE60115667T patent/DE60115667T2/de not_active Expired - Lifetime
- 2001-09-03 HU HU0303379A patent/HUP0303379A3/hu unknown
- 2001-09-03 AU AU2001287801A patent/AU2001287801A1/en not_active Abandoned
- 2001-09-03 US US10/129,262 patent/US20050085426A1/en not_active Abandoned
- 2001-09-03 KR KR10-2003-7003237A patent/KR20030040441A/ko not_active Application Discontinuation
- 2001-09-03 JP JP2002525131A patent/JP2004508364A/ja not_active Withdrawn
- 2001-09-03 AT AT01967418T patent/ATE312088T1/de not_active IP Right Cessation
- 2001-09-03 CN CN01815200A patent/CN1452617A/zh active Pending
- 2001-09-03 CA CA002421179A patent/CA2421179A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HUP0303379A2 (hu) | 2004-01-28 |
WO2002020510A1 (fr) | 2002-03-14 |
MXPA03001876A (es) | 2004-09-10 |
CN1452617A (zh) | 2003-10-29 |
JP2004508364A (ja) | 2004-03-18 |
KR20030040441A (ko) | 2003-05-22 |
EP1317439B1 (de) | 2005-12-07 |
CA2421179A1 (en) | 2002-03-14 |
IL154736A0 (en) | 2003-10-31 |
AU2001287801A1 (en) | 2002-03-22 |
EP1317439A1 (de) | 2003-06-11 |
US20050085426A1 (en) | 2005-04-21 |
ATE312088T1 (de) | 2005-12-15 |
HUP0303379A3 (en) | 2004-03-01 |
DE60115667T2 (de) | 2006-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Metal-organic frameworks for stimuli-responsive drug delivery | |
Xie et al. | O2-Cu/ZIF-8@ Ce6/ZIF-8@ F127 composite as a tumor microenvironment-responsive nanoplatform with enhanced photo-/chemodynamic antitumor efficacy | |
Cai et al. | Metal–organic framework‐based stimuli‐responsive systems for drug delivery | |
Rojas et al. | Metal organic frameworks based on bioactive components | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
BR0009176A (pt) | Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular | |
RU2008112146A (ru) | Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью | |
MD20070267A (en) | Gastroresistant pharmaceutical formulation containing rifaximin | |
DK1372608T3 (da) | Medicinske aerosolformuleringer | |
NO20025621D0 (no) | Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser | |
DE60038183D1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
CN103563983A (zh) | 一种纳米银过氧化物复合杀菌液及其制备方法 | |
Dua et al. | Investigation of enhancement of solubility of norfloxacin β-cyclodextrin in presence of acidic solubilizing additives | |
ECSP066663A (es) | Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso | |
BRPI0413957A (pt) | processo para preparar diterpenos solúveis em água, solução aquosa e suas aplicações | |
DE60115667D1 (de) | Säureempfindliche verbindungen, deren herstellung und verwendungen | |
ES2855985T3 (es) | Agente terapéutico para su uso en el tratamiento de infecciones | |
EA200200151A1 (ru) | Сухая порошкообразная композиция | |
Wang et al. | Carborane based mesoporous nanoparticles as a potential agent for BNCT | |
MXPA02001804A (es) | Composicion para inhalacion que comprende delta-9-tetrahidrocanabinol en un solvente semi-acuoso. | |
EA201070626A1 (ru) | Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества | |
JP2006052172A5 (de) | ||
RU2693410C1 (ru) | Композиция с супрамолекулярной структурой коллоидной смеси комплексных соединений наноструктурных частиц серебра или гидрозоля катионов серебра в водном или в водно-органическом растворе, обладающая антимикробным и антитоксическим действием (варианты), и способ ее получения | |
CZ300120B6 (cs) | Farmaceutická kompozice pro injekcní podání | |
Gowri et al. | Proniosome: a novel approach to vesicular drug delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: BOCKHORNI & KOLLEGEN, 80687 MUENCHEN |